Organovo Holdings - Stock Price History | ONVO

Historical daily share price chart and data for Organovo Holdings since 2021 adjusted for splits. The latest closing stock price for Organovo Holdings as of September 27, 2021 is 7.13.
  • The all-time high Organovo Holdings stock closing price was 255.00 on November 18, 2013.
  • The Organovo Holdings 52-week high stock price is 23.92, which is 235.5% above the current share price.
  • The Organovo Holdings 52-week low stock price is 6.05, which is 15.1% below the current share price.
  • The average Organovo Holdings stock price for the last 52 weeks is 9.61.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Organovo Holdings Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 9.2922 7.6020 17.8440 4.2000 12.3000 72.90%
2019 12.7792 20.0000 22.8000 5.0060 7.1140 -62.84%
2018 24.4593 27.8000 39.8000 18.6000 19.1420 -28.57%
2017 49.2717 73.1000 77.6000 26.8000 26.8000 -60.47%
2016 61.7040 48.4000 96.2000 34.6000 67.8000 36.14%
2015 82.5841 145.8000 145.8000 41.8000 49.8000 -65.66%
2014 152.6587 225.8000 232.2000 107.0000 145.0000 -34.51%
2013 110.0625 47.2000 255.0000 47.2000 221.4000 325.77%
2012 54.2443 33.0000 193.0000 24.8000 52.0000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.062B $0.002B
Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29